CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
|Articles|October 15, 2002
- BioPharm International-10-01-2002
- Volume 15
- Issue 10
Virus Inactivation in the 1990s ? and into the 21st Century: Part 3b, Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)
Author(s)Gail Sofer
by Gail Sofer, BioReliance The latest installment of our series on recently published methods for inactivating viruses reviews the literature on virus inactivation in plasma and plasma products by chemical treatments, gamma and UV irradiation, and low-pH treatment.
Advertisement
Articles in this issue
about 24 years ago
FDA Launches Major CGMP Reviewabout 24 years ago
Process Validation: How Much to Do and When to Do Itabout 24 years ago
Biotech Will Recover!about 24 years ago
GMPs and Pharmaceutical Labelingabout 24 years ago
Revolutionizing Biologics RegulationAdvertisement
Related to this article
AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
Three case studies show how automated Raman plate reading can triage samples before chromatography in bioprocess development.
This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
Advertisement
Advertisement
Trending on BioPharm International
1
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
2
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
3
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
4
Resolving the Speed-Specificity Trade-Off in Biopharma High-Throughput Screening
5